John Lem News Today

Entheon Biomedical Corp. Launches HaluGens Psychedelics Genetic Test HaluGens DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industrys first Psychedelics Genetic Test ...

Ottawa biotech firm predicts revenues will top $200 million this year ​– and only rise from there.